Skip to main content

Table 1 Characteristics of subjects under analysis with duration and number of treatments

From: Effect of high-dose intravenous vitamin C on inflammation in cancer patients

Type of cancer Age Sex CRP before CRP after Days of treatment Number of treatments Conventional treatment
Anorectal adenocarcinoma, grade 3, invasive 60 F 19.6 1.9 663 4 low anterior resection, colorectostomy
Biliary cancer, cholangiocarcinoma S-III(IV) 77 M 19.58 143.76 68 33 No records (NR)
Bladder - transitional cell carcinoma x 2, grade 3 66 M 57.5 11 76 7 operations, post treatment cycles
Bladder, grade 3 65 M 6.09 0.94 167 7 2 times surgery
Breast 71 M 6.2 3.1 179 2 mastectomy, Tomoxifen
Breast 57 F 19.4 0.4 512 47 NR
Breast 82 F 22 8.9 132 2 radiation, 36 treatments
Breast 66 F 12 2.25 193 3 Lamoxifin - 1.5 year
Breast 89 F 4.1 8.5 454 19 NR
Breast, ductal carcinoma in situ, high nuclear grade 67 F 21.1 5.5 555 12 no surgery
Breast carcinoma in situ, Basal cell carcinoma, Lymphoma 71 F 133.2 2.3 682   surgery, mastectomy, chemotherapy
Breast, category 5 78 F 8.6 13.1 379 20 NR
Breast, poorly differentiated duct cell carcinoma grade 4, Pancreas, malignant stage III, nonresectable 78 F 3.7 8.9 233 4 no radiation or chemotherapy, mastectomy
Breast, infiltrating tubular carcinoma 77 F 2.7 7.9 232 3 no radiation, chemotherapy or mastectomy
Breast, stage 1, T1 OMO, grade 2 53 F 12 3.8 44 11 lumpectomy
Breast, Stage IIA; Nottingham grade 2 69 F 9.3 3 121 20 breast lumpectomy; partial mastectomy; excision (L) breast;
Colon, stage IV, liver cancer 64 M 44 3.4 232 12 surgery, chemotherapy, hepatic resection
Gastric cancer 70 M 1.6 59.8 159 15 NR
Large B cell lymphoma 25 F 10.5 0.3 82 18 NR
Lung 65 M 216 35.9 174 27 NR
Lung - squamous cell, grade 2 80 M 9 6.7 82 20 surgery, no chemotherapy
Lung, renal 82 F 19.2 59 167 37 NR
Lymphoma 53 F 10.8 5.2 110 5 Immune therapy 4 treatments/week every 6 months, Rutuxin
Pancreas 85 M 3.8 54.5 42 11 NR
Pancreas, breast 71 F 10.1 0.4 119 44 NR
Pancreas, liver and bone metastasis 89 M 2 25 423   cholecystojejunostomy and gastrojejunostomy
Pros, Gleason score 6-8 82 M 3.9 8.8 279 8 no surgery or hormonal therapy
Prostate 77 M 26.2 0.4 261 16 NR
Prostate 80 M 153.3 148.4 11 5 NR
Prostate 93 M 29.2 2.1 136 20 NR
Prostate, colon cancer 89 M 43.4 31.5 113 5 chemotherapy, colonectomy
Prostate, Gleason score 2.5, malignant skin melanoma 72 M 6 0.9 140 8 NR
Prostate, Gleason score 6 53 M 8.4 1.9 38 4 surgery
Prostate, Gleason score 6, squamous cell melanoma, bone cancer 78 M 35.5 1.3 23 4 radical prosectomy
Prostate, Gleason score 6, stage T2A 72 M 22.1 3.66 400   surgery
Prostate, Gleason score 7 78 M 16.7 4.8 401 4 radiation and hormonal therapy
Prostate, pancreas 74 M 14.9 40.7 89 24 NR
Prostate, pancreas 86 M 500 54.3 542 102 NR
Prostate, stage I 65 M 2.53 8.59 82 1 prostatectomy
Prostate, Gleason score 4, increased to 6–9 during 2 years 81 M 5 0.6 1449 3 NR
Prostate, Esophageal cancer 84 M 15.3 3.1 37 6 removal of esophagus
Prostate, metastatic adenocarcinoma, Gleason score 4 + 4 = 8 74 M 25 0.7 791 7 radical prostatectomy
Rectal adenocarcinoma, invasive through muscle layer 71 M 2.2 7.2 137 2 chemotherapy radiation
Renal, Basal cell carcinoma 82 M 30.5 19.5 48 10 operation, 33 treatments by radiation
Skin, B-cell Lymphoma, Lung 83 M 8.9 1.5 754 36 surgery, 40 radiations